Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Franco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ciro Gallo(University of Campania "Luigi Vanvitelli"), L Brancaccio, Antônio Rossi(Università Campus Bio-Medico), G. Pappagallo, S. Zonato, GP Ianniello, L. Zuccarino, Rosa Aiello, Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), S. Cigolari(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Luigi Maiorino(Medical Center Hospital), T Pedicini, S. Monfardini
Cited by 18
Related Papers
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation
|European Respiratory Journal|2005|383
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234